Latest news
Analyst Reiterates Buy on Prothena, Citing Disciplined Capital Strategy and Undervalued TTR Franchise with Unchanged $30 Price Target - tipranks.comtipranks.com · Fri, 07 Aug 2026 15:11:37 GMTAnalyst Reaffirms Buy on Korro Bio, Citing Undervalued OPERA RNA Editing Platform and Multi-Billion-Dollar Pipeline Potential - tipranks.comtipranks.com · Fri, 07 Aug 2026 12:27:18 GMTAnalyst Reaffirms Buy on Context Therapeutics, Citing Undervalued Pipeline and CTIM-76 as Key Long-Term Driver - tipranks.comtipranks.com · Thu, 06 Aug 2026 17:52:17 GMTMirae Asset lifts Celltrion target, cites undervaluation vs Sandoz - CHOSUNBIZ - ChosunbizChosunbiz · Tue, 28 Jul 2026 07:00:00 GMT